ATE408838T1 - Auf hsc70 gerichtete diagnostika und therapeutika für eine gegen mehrere arzneistoffe resistente tumorerkrankung - Google Patents

Auf hsc70 gerichtete diagnostika und therapeutika für eine gegen mehrere arzneistoffe resistente tumorerkrankung

Info

Publication number
ATE408838T1
ATE408838T1 AT03814521T AT03814521T ATE408838T1 AT E408838 T1 ATE408838 T1 AT E408838T1 AT 03814521 T AT03814521 T AT 03814521T AT 03814521 T AT03814521 T AT 03814521T AT E408838 T1 ATE408838 T1 AT E408838T1
Authority
AT
Austria
Prior art keywords
hsc70
diagnostics
drug resistant
tumor disease
resistant tumor
Prior art date
Application number
AT03814521T
Other languages
English (en)
Inventor
Elias Georges
Lucile Serfass
Anne-Marie Bonneau
Frederic Dallaire
Original Assignee
Aurelium Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurelium Biopharma Inc filed Critical Aurelium Biopharma Inc
Application granted granted Critical
Publication of ATE408838T1 publication Critical patent/ATE408838T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT03814521T 2003-01-03 2003-12-15 Auf hsc70 gerichtete diagnostika und therapeutika für eine gegen mehrere arzneistoffe resistente tumorerkrankung ATE408838T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43801203P 2003-01-03 2003-01-03

Publications (1)

Publication Number Publication Date
ATE408838T1 true ATE408838T1 (de) 2008-10-15

Family

ID=32713265

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03814521T ATE408838T1 (de) 2003-01-03 2003-12-15 Auf hsc70 gerichtete diagnostika und therapeutika für eine gegen mehrere arzneistoffe resistente tumorerkrankung

Country Status (8)

Country Link
US (2) US7226748B2 (de)
EP (1) EP1588162B1 (de)
JP (1) JP2006512579A (de)
AT (1) ATE408838T1 (de)
AU (1) AU2003300676A1 (de)
CA (1) CA2512513A1 (de)
DE (1) DE60323682D1 (de)
WO (1) WO2004061458A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033514A1 (en) 2001-10-19 2003-04-24 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
WO2005062058A1 (en) * 2002-12-13 2005-07-07 Aurelium Biopharma Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7413851B2 (en) 2002-12-13 2008-08-19 Aurelium Biopharma, Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7358042B2 (en) * 2003-03-14 2008-04-15 Aurelium Biopharma, Inc. Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease
DE102004052889A1 (de) * 2004-11-02 2006-05-11 Ruprecht-Karls-Universität Heidelberg Screeningverfahren zur Früherkennung des zerebralen Vasospasmus
US20060159681A1 (en) * 2004-12-14 2006-07-20 Functional Neuroscience Inc. Compositions and methods to inhibit cell loss by using inhibitors of BAG
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
WO2007028141A2 (en) * 2005-08-31 2007-03-08 The Johns Hopkins University Imaging agents and methods of using same for detecting multidrug resistance in cancer
WO2007072221A2 (en) * 2005-11-10 2007-06-28 Aurelium Biopharma Inc. Surface marker-directed cancer therapeutics
JPWO2007136026A1 (ja) * 2006-05-19 2009-10-01 忠和 鄭 抗原タンパク質の定量方法及び定量用キット
GB0705626D0 (en) * 2007-03-23 2007-05-02 Royal Veterinary College Method for enhancing sperm survival
JP2010538655A (ja) * 2007-09-12 2010-12-16 アナフォア インコーポレイテッド 自己免疫疾患についてのｈｓｐ７０に基づく治療
US20090191126A1 (en) * 2007-11-27 2009-07-30 The Regents Of The University Of California Peptide and multivalent peptide conjugate for diagnosis and treatment of vascular plaques
WO2018048936A1 (en) * 2016-09-06 2018-03-15 Incelldx, Inc. Methods of detecting per cell pd-l1 expression and uses thereof
US11726089B2 (en) 2016-09-06 2023-08-15 Incelldx, Inc. Methods of assaying neoplastic and neoplasia-related cells and uses thereof
WO2019118734A1 (en) * 2017-12-13 2019-06-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating motor neuron diseases
CN114805518B (zh) * 2022-05-31 2023-10-13 河南牧业经济学院 一种具有免疫调节活性的蛋白wg-sp01
WO2024050560A1 (en) * 2022-09-02 2024-03-07 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating neurodegeneration

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720386A (en) * 1976-11-24 1988-01-19 Mccollester Duncan L Vaccine and method for immunotherapy of neoplastic disease
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US5081154A (en) * 1984-01-10 1992-01-14 Aktiebolaget Hassle Metoprolol succinate
US6338853B1 (en) * 1987-04-23 2002-01-15 Jean-Claude Bystryn Anti-cancer vaccine
US5194384A (en) * 1987-04-23 1993-03-16 Bystryn Jean Claude Method for preparing human meloma vaccine
US5994088A (en) * 1991-03-08 1999-11-30 Board Of Trustees Of The University Of Illinois Methods and reagents for preparing and using immunological agents specific for P-glycoprotein
DE4112999C2 (de) 1991-04-20 1994-11-24 Klaus Dr Med Ritter Verfahren und Nachweismittel zum Nachweis einer Infektion mit dem Epstein-Barr Virus
US5407653A (en) * 1991-06-26 1995-04-18 Brigham And Women's Hospital Evaluation of the multidrug resistance phenotype
WO1994008038A1 (en) 1992-10-02 1994-04-14 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
IL123219A0 (en) * 1995-08-18 1998-09-24 Sloan Kettering Inst Cancer Method for treatment of cancer and infectious diseases and compositions useful in same
US6406689B1 (en) * 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
JPH107559A (ja) * 1996-06-18 1998-01-13 Kureha Chem Ind Co Ltd Ｈｓｐ２７ファミリーに属するタンパク質のベルベリン誘導体含有合成抑制剤
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US6403308B1 (en) * 1997-04-30 2002-06-11 Mcgill University Methods for detecting and reversing resistance to macrocyclic lactone compounds
AU2903999A (en) * 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
US6623923B1 (en) * 1998-12-23 2003-09-23 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US6572856B1 (en) * 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6476193B1 (en) * 1998-10-06 2002-11-05 Curagen Corporation NLK1 protein and NLK1 protein complexes
US6475490B1 (en) * 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US20020177212A1 (en) * 1999-05-17 2002-11-28 Board Of Regents, The University Of Texas System Polypeptide that interacts with heat shock proteins
JP3829226B2 (ja) * 1999-07-07 2006-10-04 独立行政法人理化学研究所 ビメンチンの切断産物に対する抗体
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6657048B2 (en) * 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6730514B2 (en) 2000-12-07 2004-05-04 Ranju Ralhan Stable human oral cancer cell carcinoma cell line
HUP0100948A2 (hu) 2001-03-02 2003-02-28 Gábor Szabó Antitest kompeticiós teszt (AKT) P-glikoprotein és egyéb sejtfelszíni receptorok, pumpák és fehérjék konformáció-változásainak kvalitatív, illetve konformáció-függő kvantitatív kimutatására és annak alkalmazásai
CZ20032787A3 (en) 2001-04-03 2004-03-17 Merck Patent Gmbh Renal cell carcinoma tumor markers
US6875849B2 (en) * 2001-05-01 2005-04-05 Arizona Board Of Regents Of Behalf Of The University Of Arizona Methods of recovering chaperone proteins and complexes thereof
US20020198139A1 (en) * 2001-05-17 2002-12-26 Deutschman Clifford S. Method of preventing acute pulmonary cell injury
FR2826780A1 (fr) * 2001-06-28 2003-01-03 St Microelectronics Sa Dispositif semi-conducteur a structure hyperfrequence
WO2003008542A2 (en) 2001-07-16 2003-01-30 Gene Logic, Inc. Nucleic acid detection assay control genes
US20030157081A1 (en) * 2001-10-26 2003-08-21 Bonini Nancy M. Methods and compositions for suppression of neurodegeneration
US6828113B2 (en) * 2002-03-21 2004-12-07 Cornell Research Foundation, Inc. IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection
WO2005062058A1 (en) * 2002-12-13 2005-07-07 Aurelium Biopharma Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease

Also Published As

Publication number Publication date
AU2003300676A1 (en) 2004-07-29
EP1588162A2 (de) 2005-10-26
EP1588162B1 (de) 2008-09-17
US20040185511A1 (en) 2004-09-23
CA2512513A1 (en) 2004-07-22
JP2006512579A (ja) 2006-04-13
WO2004061458A3 (en) 2004-11-25
US20090004102A1 (en) 2009-01-01
DE60323682D1 (de) 2008-10-30
WO2004061458A2 (en) 2004-07-22
US7226748B2 (en) 2007-06-05

Similar Documents

Publication Publication Date Title
ATE408838T1 (de) Auf hsc70 gerichtete diagnostika und therapeutika für eine gegen mehrere arzneistoffe resistente tumorerkrankung
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
ATE453453T1 (de) Raffinationselement
AR096317A2 (es) Molécula de adn recombinante aislada del adn genómico del evento de maíz mon88017; polinucleótido recombinante y sondas o cebadores recombinantes
DE60332484D1 (de) Ischämiedetektion auf der grundlage von reizleitungszeit
EP3284469A3 (de) Zusammensetzungen und verfahren zur erkennung lysosomaler speicherkrankheiten
DE60309017D1 (de) Brennstoffzellenanordnung und zugehöriger separator
DE60109430D1 (de) An entzündlichen darmerkrankungen beteiligte gene und deren verwendung
NO20015157L (no) Fremgangsmåte ved bestemmelse av pre-neoplastiske og/eller neoplastiske tilstander hos pattedyr
ITRM20030489A0 (it) Impianto di produzione energetica dallo sfruttamento di correnti nei fluidi.
DE602004025608D1 (de) Brennstoffzelle
DE50313671D1 (de) Verfahren zur generierung eines gentechnisch veränderten organismus für das wirksubstanzscreening
FI20020565A0 (fi) Kennorakenne, laite ja menetelmä
WO2004055517A3 (en) Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2003078603A3 (en) Strong gene sets for glioma classification
FR2850178B1 (fr) Clavier universel.
DE60015564D1 (de) Berechnungsmethoden zur herstellung von molekularen mimetika
TW200643894A (en) Music editing methods and related devices
WO2006042005A3 (en) Global gene expression profiling of circulating tumor cells
DE60327776D1 (de) Sonden zum nachweis von tumorzellen
WO2004080819A3 (en) Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease
ATE526402T1 (de) Hilfssonden und verfahren zur verwendung davon
FR2866600B1 (fr) Instrument d'ecriture
FR2869568B1 (fr) Instrument d'ecriture
Nguyen Azide addition in Iridium isocyanide complexes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee